Hemogenyx Pharmaceuticals (HEMO) Competitors

OKYO Pharma (LON:OKYO) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Does the media refer more to OKYO or HEMO?

In the previous week, OKYO Pharma's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
OKYO Pharma	Neutral
Hemogenyx Pharmaceuticals	Neutral

Which has preferable valuation & earnings, OKYO or HEMO?

Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-£6.70M	-£0.01	N/A
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£0.20	-1,010.32

Which has more volatility and risk, OKYO or HEMO?

OKYO Pharma has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500. Comparatively, Hemogenyx Pharmaceuticals has a beta of 3.14, suggesting that its stock price is 214% more volatile than the S&P 500.

Do institutionals and insiders have more ownership in OKYO or HEMO?

0.8% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 31.9% of OKYO Pharma shares are held by insiders. Comparatively, 10.7% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community favor OKYO or HEMO?

Hemogenyx Pharmaceuticals received 48 more outperform votes than OKYO Pharma when rated by MarketBeat users. However, 63.64% of users gave OKYO Pharma an outperform vote while only 57.89% of users gave Hemogenyx Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
OKYO Pharma	Outperform Votes 7 63.64%	Underperform Votes 4 36.36%
Hemogenyx Pharmaceuticals	Outperform Votes 55 57.89%	Underperform Votes 40 42.11%

Is OKYO or HEMO more profitable?

Hemogenyx Pharmaceuticals' return on equity of -80.66% beat OKYO Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	-397.13%	-154.72%
Hemogenyx Pharmaceuticals	N/A	-80.66%	-37.79%

Summary

Hemogenyx Pharmaceuticals beats OKYO Pharma on 6 of the 10 factors compared between the two stocks.